New Lundbeck candidate to kick off R&D division

With the acquisition of the biotherapy candidate from South Korean Aprilbio, Lundbeck has obtained the first development program within a new strategic focus area, neuroimmunology. Lundbeck's EVP and research lead is keeping his cards close about potential drug indications.

Photo: PR / Lundbeck

Since Lundbeck went through a larger shift in its research and development division, the company has been busy scouting for assets that could fit in its new focus area, neuroinflammation or neuroimmunology.

This has resulted in the purchase of the phase I-ready antibody APB-A1 from the South Korean company Aprilbio, and Lundbeck's Head of Research and Development Johan Luthman is excited to finally have the first real candidate in the company's new area.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Further reading

Related articles

Trial banner

Latest news

See all jobs